Network Point-of-Care Glucose Testing Market Outlook

Network Point-of-Care Glucose Testing Market Outlook (2022 to 2032)

The global Network Point-of-Care Glucose Testing Market was valued at around US$ 1.5 billion in 2021. With a projected CAGR of 4.8% for the next ten years, the market is likely to reach a valuation of nearly US$ 2.5 billion by the end of 2032. The Global absolute dollar opportunity growth in network point-of-care glucose testing is projected to be at US$ 923.3 million by 2032.

Attributes	Details
Network Point-of-Care Glucose Testing Market Size (2021)	US$ 1.5 billion
Network Point-of-Care Glucose Testing Market Size (2022)	US$ 1.6 billion
Projected Market Value (2032)	US$ 2.5 billion
Global Market Growth Rate (2022 to 2032)	4.8% CAGR
Key Companies Profiled	F. Hoffmann-La Roche Ltd. Danaher. Abbott Nipro PlatInium Equity Advisors, LLC Nova Biomedical ACON Laboratories Trividia Health, Inc. Prodigy Diabetes Care, LLC Bayer AG/Ascensia Diabetes Care Holdings AG EKF Diagnostics

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Network Point-of-care Glucose Testing Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Network point-of-care glucose testing is a growing testing method that does not require testing in the laboratory but is instead performed near or at the site of the patient to monitor the glucose levels. This ensures minimal risk of infection and provides information within a few seconds.

Future Market Insights reveals that revenue from Accu-Chek Inform II dominated the segment of product type. Revenue from Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. It is projected to achieve a growth rate of 4.9% during the forecasted period of 2022 to 2032. On the other hand, North America dominated the market for network-point-of-care glucose testing. It achieved a growth rate of 4.8% from 2017 to 2021 and is projected to witness revenue growth of 4.9% CAGR over the forecasted period.

How the management of patient data and remote patient monitoring is driving the market for network-point-of-care glucose testing?

Network Point-of-care glucose testing is significantly gaining traction for the diagnosis of diabetes as well as for analyzing patients’ health conditions. It has come as an efficient tool for preventing delays in treatment and providing results in less time. Moreover, the demand for remote patient monitoring systems and the need for data-based patient results are driving the market for network point-of-glucose testing.

As the number of diabetes patients is surging, there is an increasing demand to incorporate the patient data and perform proper management of the data to derive insightful information and develop an advanced method for data transfer techniques.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How growing incidence of diabetes among older adults is influencing the growth of the network-point-of-care glucose testing market?

The growing incidence of diabetes necessitates glucose testing among individuals. According to WHO data, 422 million people globally are suffering from diabetes, the majority of whom are living in underdeveloped countries. Therefore, the treatment of glucose testing becomes vital for these nations as they remain undiagnosed and are at risk of developing diseases associated with diabetes such as blindness, kidney failure, stroke, and heart attack.

Based on a WHO report in 2019, diabetes contributed to the ninth leading cause of death with an estimation of 1.5 million deaths. According to Diabetes Federation data published in 2021, almost 1 in 2 diabetes patients were undiagnosed, and in Asia-Pacific, the proportion was estimated to be 55%, largely contributed by India, China, and Indonesia. Therefore, it becomes essential to expand the coverage of network point-of-care glucose testing methods in low and middle-income countries as well as developed countries.

Regional Insights

How is the market for Network point-of-care glucose testing in North America expected to perform in forthcoming years?

North America is the largest user of network point-of-care testing methods. Revenue through Network point-of-care glucose testing grew at a CAGR of 4.8% from 2017 to 2021. North America is expected to dominate the market with a 4.9% CAGR from 2022 to 2032. Prominent key players such as Abbott, Nova Medical, and prodigy Diabetes Care, LLC are aiding the regional market growth. Moreover, several initiatives by the government and not-for-profit organizations to increase awareness about the adoption of advanced glucose meters are driving growth in North America.

Country-wise Insights

The USA Network point-of-care glucose testing Market Analysis

The network point-of-care glucose testing market in the USA was valued at US$ 735 million by 2032. Revenue through the market grew at 4.6% CAGR from 2017 to 2021. The projected growth rate in the network point-of-care glucose testing market is 4.9% over the forecasted period. According to the data from American Diabetes Association, almost 37.3 million Americans, or 11.3% of the population had diabetes in 2019. Out of which 8.5 million were undiagnosed and 244,000 children and adolescents in the USA were suffering from diabetes. This necessitates the need for conducting point-of-care glucose testing among individuals and ensuring early recovery from chronic disease.

Key companies like Abbott had maintained their presence in the USA market by providing FreeStyl e Libre 2 integrated continuous glucose monitoring system which is used by the most number of Americans to track health statistics in a mobile app. The absolute dollar opportunity growth in the network point-of-care glucose testing market in the USA is US$ 276.2 million by 2032.

The United Kingdom Network point-of-care glucose testing Market Analysis

The network point-of-care glucose testing market in the United Kingdom is projected to reach a valuation of US$ 119 million by 2032. Growing at a CAGR of 5.8%, the market is expected to register an absolute dollar opportunity of US$ 50.6 million from 2022 to 2032.

Japan Network point-of-care glucose testing Market Analysis

The market in Japan is expected to gross an absolute dollar opportunity of US$ 36 million during the forecast period. Growing at a CAGR of 4.5%, the market is likely to reach a valuation of US$ 101 million by 2032.

South Korea Network point-of-care glucose testing Market Analysis

In South Korea, the market is projected to reach a valuation of US$ 59 million by 2032. Growing at a CAGR of 4.9%, the market from 2022 to 2032 is expected to gross an absolute dollar opportunity of US$ 23 million.

Category-wise Insights

Why is the demand for Accu-Chek Inform II rising in Network Point-of-care glucose testing market?

Accu-Chek Inform II is widely used as a point-of-care glucose testing monitor. Revenue through Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. The anticipated growth rate of Accu-Chek Inform II is 4.9% during the forecasted period of 2022 to 2032. The rise in the use of Accu-Chek Inform II is attributed to its automatic real-time wireless features which enable proper transmission of patient data between the medical staff and the laboratories. The system also offers unique features such as unique identification of patients to avoid inaccuracy.

How is the market for network point-of-care glucose testing shaping up in Asia-Pacific?

Due to the prevalence of diabetes in Asia, the network point-of-care glucose testing market is expected to witness growth in the forecasted period. Almost 90 million adults are suffering from diabetes in the IDF South-East Asia region and is estimated to witness a spike in diabetes patients to 152 million by 2045. Countries in the Asia-Pacific have made efforts to employ point-of-care glucose testing methods to reduce the occurrence of diabetes. For instance, in China, the government incentivized hospitals to employ diabetes management systems. Hospitals in Tianjin have administered blood glucose information systems to improvise blood glucose monitoring, treatment, and management.

Competitive Landscape

Companies involved in network point-of-care glucose testing are solely aiming at increasing diabetes awareness and producing advanced point-of-care glucose testing devices. The key companies operating in the network point-of-care glucose testing market include F. Hoffmann-La Roche Ltd. Danaher, Abbott, Nipro, Platinum Equity Advisors, LLC (Lifescan, Inc.), Nova Biomedical, ACON Laboratories, Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics and others.

Some of the recent developments by key providers of Network Point-of-Care Glucose Testing are as follows:

In January 2022, to manage blood glucose solutions, Roche announced the release of the Cobas pulse system. It is meant to be the first diagnostic tool available at the point of care and give users a way to communicate with the creators of digital health software and applications. As a result, clinical insights will be made simpler and patient care will be improved.
In October 2021, EKF diagnostics introduced a handheld analyzer STAT-Site WB. It is primarily used for the determination of β-ketone and glucose measurements from the whole blood in seconds. It uses two different test strips to send results in 10 seconds for β-ketones and 5 seconds for glucose.
In May 2020, EKF Diagnostics Collaborated with Tosoh Europe N.V. for the distribution of a Quo-Test HbA1c point-of-care (POC) analyzer in the Middle East and Africa. The aim of the collaboration is to expand the need for those who are at a greater risk of suffering from diabetes.
In September 2019, an On Call Express Voice was made available in the USA market by ACON laboratories. This feature complements the family of blood glucose meters produced by ACON laboratories. To assist the user and get the most out of the audible blood glucose meter, it includes navigation and an audio feature.

Similarly, recent developments related to companies operating in the network point-of-care glucose testing market have been tracked by the team at Future Market Insights, which is available in the full report.

Key Segments Covered in Network Point-of-Care Glucose Testing Industry Survey

Network Point-of-Care Glucose Testing Market by Product Type:

i-STAT
Accu-Chek Inform II
Stat Strip
Hemo Cue
Care Sens Expert Plus
BARO-zen H Expert Plus

Network Point-of-Care Glucose Testing Market by Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Frequently Asked Questions

How much is the global Network Point-of-Care Glucose Testing Market currently worth?

The global Network Point-of-Care Glucose testing market was valued at US$ 1.5 billion in 2021 and US$ 1.6 billion in 2022.

What is the Network Point-of-Care Glucose Testing Market Forecast through 2032?

The Network Point-Of-Care glucose testing industry is set to witness a high growth rate of 4.8% over the forecast period and is valued at US$ 2.5 by 2032.

Which Product type dominated the market for Network Point-of-Care glucose testing?

Accu-Chek Inform II maintained its largest share and grew at a CAGR of 4.5% from 2017 to 2021.

Who are the key players shaping the Network Point-of-Care Glucose testing industry?

F. Hoffmann-La Roche Ltd., Danaher, Abbott, Nipro, Platinum Equity Advisors, LLC (Lifescan, Inc.), Nova Biomedical, ACON Laboratories, Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics are the key operators in Network Point-of-Care Glucose Testing market.

Which region maintained its highest share in the market for Network Point-of-Care Glucose Testing?

North America dominates the market for network point-of-care glucose testing with 4.8% CAGR from 2017 to 2021. The anticipated growth rate of North America is 4.9% during the forecasted period.

Which Countries are driving highest demand for Network Point-of-care Glucose testing market?

The USA, United Kingdom, China, Japan, and South Korea are expected to drive the highest demand for the Network Point-of-Care Glucose testing market.

What is the North America market outlook for Network Point-of-Care Glucose Testing?

Revenue through the Network Point-of-Care Glucose testing market in North America grew by 4.8% from 2017 to 2021. The projected growth rate in North American in-network point-of-care glucose testing is 4.9% over the forecasted period.

What is the USA market outlook for Network Point-of-Care Glucose Testing?

The Network Point-of-Care Glucose testing market in the USA is valued at US$ 735 million in 2032 and is expected to achieve a growth rate of 4.9% during the forecasted year.

Table of Content

1. Executive Summary | Network Point-of-Care Glucose Testing Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Investment Feasibility Matrix

3.6. PESTLE and Porter’s Analysis

3.7. Regulatory Landscape

3.7.1. By Key Regions

3.7.2. By Key Countries

3.8. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032

4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2021

4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ million) Analysis By Product Type, 2017 to 2021

5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Product Type, 2022 to 2032

5.3.1. i-STAT

5.3.2. Accu-Chek Inform II

5.3.3. StatStrip

5.3.4. HemoCue

5.3.5. CareSens Expert Plus

5.3.6. BAROzen H Expert Plus

5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2021

5.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032

6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region

6.1. Introduction

6.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2021

6.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032

6.3.1. North America

6.3.2. Latin America

6.3.3. Europe

6.3.4. Asia Pacific

6.3.5. Middle East and Africa

6.4. Market Attractiveness Analysis By Region

7. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

7.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

7.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

7.2.1. By Country

7.2.1.1. The USA

7.2.1.2. Canada

7.2.2. By Product Type

7.3. Market Attractiveness Analysis

7.3.1. By Country

7.3.2. By Product Type

7.4. Key Takeaways

8. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

8.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

8.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

8.2.1. By Country

8.2.1.1. Brazil

8.2.1.2. Mexico

8.2.1.3. Rest of Latin America

8.2.2. By Product Type

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Product Type

8.4. Key Takeaways

9. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

9.2.1. By Country

9.2.1.1. Germany

9.2.1.2. The United Kingdom

9.2.1.3. France

9.2.1.4. Spain

9.2.1.5. Italy

9.2.1.6. Russia

9.2.1.7. Rest of Europe

9.2.2. By Product Type

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Product Type

9.4. Key Takeaways

10. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

10.2.1. By Country

10.2.1.1. China

10.2.1.2. Japan

10.2.1.3. India

10.2.1.4. South Korea

10.2.1.5. Australia

10.2.1.6. Rest of APAC

10.2.2. By Product Type

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Product Type

10.4. Key Takeaways

11. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country

11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

11.2.1. By Country

11.2.1.1. South Africa

11.2.1.2. Saudi Arabia

11.2.1.3. UAE

11.2.1.4. Israel

11.2.1.5. Rest of Middle East and Africa (MEA)

11.2.2. By Product Type

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Product Type

11.4. Key Takeaways

12. Key Countries Market Analysis

12.1. The USA

12.1.1. Pricing Analysis

12.1.2. Market Share Analysis, 2021

12.1.2.1. By Product Type

12.2. Canada

12.2.1. Pricing Analysis

12.2.2. Market Share Analysis, 2021

12.2.2.1. By Product Type

12.3. Brazil

12.3.1. Pricing Analysis

12.3.2. Market Share Analysis, 2021

12.3.2.1. By Product Type

12.4. Mexico

12.4.1. Pricing Analysis

12.4.2. Market Share Analysis, 2021

12.4.2.1. By Product Type

12.5. Germany

12.5.1. Pricing Analysis

12.5.2. Market Share Analysis, 2021

12.5.2.1. By Product Type

12.6. The United Kingdom

12.6.1. Pricing Analysis

12.6.2. Market Share Analysis, 2021

12.6.2.1. By Product Type

12.7. France

12.7.1. Pricing Analysis

12.7.2. Market Share Analysis, 2021

12.7.2.1. By Product Type

12.8. Spain

12.8.1. Pricing Analysis

12.8.2. Market Share Analysis, 2021

12.8.2.1. By Product Type

12.9. Italy

12.9.1. Pricing Analysis

12.9.2. Market Share Analysis, 2021

12.9.2.1. By Product Type

12.10. Russia

12.10.1. Pricing Analysis

12.10.2. Market Share Analysis, 2021

12.10.2.1. By Product Type

12.11. China

12.11.1. Pricing Analysis

12.11.2. Market Share Analysis, 2021

12.11.2.1. By Product Type

12.12. Japan

12.12.1. Pricing Analysis

12.12.2. Market Share Analysis, 2021

12.12.2.1. By Product Type

12.13. India

12.13.1. Pricing Analysis

12.13.2. Market Share Analysis, 2021

12.13.2.1. By Product Type

12.14. South Korea

12.14.1. Pricing Analysis

12.14.2. Market Share Analysis, 2021

12.14.2.1. By Product Type

12.15. Australia

12.15.1. Pricing Analysis

12.15.2. Market Share Analysis, 2021

12.15.2.1. By Product Type

12.16. South Africa

12.16.1. Pricing Analysis

12.16.2. Market Share Analysis, 2021

12.16.2.1. By Product Type

12.17. Saudi Arabia

12.17.1. Pricing Analysis

12.17.2. Market Share Analysis, 2021

12.17.2.1. By Product Type

12.18. UAE

12.18.1. Pricing Analysis

12.18.2. Market Share Analysis, 2021

12.18.2.1. By Product Type

12.19. Israel

12.19.1. Pricing Analysis

12.19.2. Market Share Analysis, 2021

12.19.2.1. By Product Type

13. Market Structure Analysis

13.1. Competition Dashboard

13.2. Competition Benchmarking

13.3. Market Share Analysis of Top Players

13.3.1. By Regional

13.3.2. By Product Type

14. Competition Analysis

14.1. Competition Deep Dive

14.1.1. F. Hoffmann-La Roche Ltd.

14.1.1.1. Overview

14.1.1.2. Product Portfolio

14.1.1.3. Profitability by Market Segments

14.1.1.4. Sales Footprint

14.1.1.5. Strategy Overview

14.1.1.5.1. Marketing Strategy

14.1.2. Danaher.

14.1.2.1. Overview

14.1.2.2. Product Portfolio

14.1.2.3. Profitability by Market Segments

14.1.2.4. Sales Footprint

14.1.2.5. Strategy Overview

14.1.2.5.1. Marketing Strategy

14.1.3. Abbott

14.1.3.1. Overview

14.1.3.2. Product Portfolio

14.1.3.3. Profitability by Market Segments

14.1.3.4. Sales Footprint

14.1.3.5. Strategy Overview

14.1.3.5.1. Marketing Strategy

14.1.4. Nipro

14.1.4.1. Overview

14.1.4.2. Product Portfolio

14.1.4.3. Profitability by Market Segments

14.1.4.4. Sales Footprint

14.1.4.5. Strategy Overview

14.1.4.5.1. Marketing Strategy

14.1.5. PlatInium Equity Advisors, LLC

14.1.5.1. Overview

14.1.5.2. Product Portfolio

14.1.5.3. Profitability by Market Segments

14.1.5.4. Sales Footprint

14.1.5.5. Strategy Overview

14.1.5.5.1. Marketing Strategy

14.1.6. Nova Biomedical

14.1.6.1. Overview

14.1.6.2. Product Portfolio

14.1.6.3. Profitability by Market Segments

14.1.6.4. Sales Footprint

14.1.6.5. Strategy Overview

14.1.6.5.1. Marketing Strategy

14.1.7. ACON Laboratories

14.1.7.1. Overview

14.1.7.2. Product Portfolio

14.1.7.3. Profitability by Market Segments

14.1.7.4. Sales Footprint

14.1.7.5. Strategy Overview

14.1.7.5.1. Marketing Strategy

14.1.8. Trividia Health, Inc.

14.1.8.1. Overview

14.1.8.2. Product Portfolio

14.1.8.3. Profitability by Market Segments

14.1.8.4. Sales Footprint

14.1.8.5. Strategy Overview

14.1.8.5.1. Marketing Strategy

14.1.9. Prodigy Diabetes Care, LLC

14.1.9.1. Overview

14.1.9.2. Product Portfolio

14.1.9.3. Profitability by Market Segments

14.1.9.4. Sales Footprint

14.1.9.5. Strategy Overview

14.1.9.5.1. Marketing Strategy

14.1.10. Bayer AG/Ascensia Diabetes Care Holdings AG

14.1.10.1. Overview

14.1.10.2. Product Portfolio

14.1.10.3. Profitability by Market Segments

14.1.10.4. Sales Footprint

14.1.10.5. Strategy Overview

14.1.10.5.1. Marketing Strategy

14.1.11. EKF Diagnostics

14.1.11.1. Overview

14.1.11.2. Product Portfolio

14.1.11.3. Profitability by Market Segments

14.1.11.4. Sales Footprint

14.1.11.5. Strategy Overview

14.1.11.5.1. Marketing Strategy

15. Assumptions & Acronyms Used

16. Research Methodology

Network Point-of-Care Glucose Testing Market

Network Point-of-Care Glucose Testing Market by Product Type & Region | Forecast 2022 to 2032